Recognising innovation in technologies, products, processes, and services to combat the impact of global healthcare emergencies on individuals, patients, healthcare professionals and communities. Including but not limited to drug or device development, rapid response, medical equipment and the introduction of services, solutions and resources to combat the impact of past and potential healthcare emergencies.

Criteria:

Innovation 

How does the entry demonstrate innovation and resourcefulness in response to healthcare emergencies? Will it inspire future development?

Purpose and Outcomes 

Does it achieve its purpose? Does it offer benefits to the audience it was designed for?

Problem-solving 

Does the entry demonstrate a unique approach to solving a particular challenge?

Competitive Advantage 

How does the entry demonstrate going above and beyond or a collaborative approach in a time of crisis?

Innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients including, but not limited to, synthesis, characterization, scale-up, software and database development, bulk manufacturing.

Criteria:

Innovation

Does the entry introduce a new idea, method or process to the market? Will it inspire broader applications?

Purpose

Does it achieve its purpose? Does it offer clear benefits or improvements over existing solutions?

Problem-solving

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage 

Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services related to the formulation of drug products including, but not limited to, excipients, finished dose, OTC, novel software and digitilisation, process development, resolving formulation challenges, bioavailability enhancement, drug targeting or controlled release and stabilization technologies.

Please note: to be eligible for this category, the activity must have taken place between Jan 2022 - August 2023.

Criteria

Innovation

Does the entry introduce a new idea, method, or novelty to the market?

Purpose

Does it achieve its purpose? Does it offer clear benefits or improvements over existing solutions?

Problem-solving

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage

Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs including, but not limited to, equipment, approaches,digitilisation, manufacturing processes, facilities, tech transfer and process controls. We welcome entries across both small and large molecule manufacturing.

Criteria

Innovation

Does the entry introduce a new idea, process, method, or novelty to the market? Will it inspire future development?

Features

Does the entry have unique qualities, abilities, or significantly improved attributes?

Problem-solving

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage

Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, solutions, processes, and services related to drug delivery, routes of administration and device innovation. Including, but not limited to, inhalers, auto-injectors, pre-filled syringes, patches, combination products, intelligent packaging and connected devices.

Criteria

Innovation

Does the entry introduce a new idea, device, method or novelty to the market? Will it inspire future development?

Features & Purpose

Does the entry have unique qualities, abilities, or improved attributes? Does it offer a significant improvement on existing market solutions?

Patient Centricity

Does the entry offer tangible improvements to patient adherence and experience?

Problem-solving

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage

Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, equipment and services for primary, secondary and tertiary packaging solutions and the packaging and assembly of finished drug products. Including but not limited to, vials, ampules, blister packs, cartons, containers, tamper-proof packaging, labelling systems, track and trace, machinery, anticounterfeiting measures and solutions which prioritise patient centricity and adherence.

Criteria

Innovation 

Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose 

Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Sustainability

Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?

Problem-solving 

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage 

Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services for ensuring the safe handling, security and tracking of drug substances, raw materials, and finished drug products. Including, but not limited to, supply chain optimisation, audits, temperature-controlled logistics, transport services, shipping and storage, anticounterfeiting, inventory management, demand forecasting and distribution channels.

Criteria

Innovation 

Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose 

Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Sustainability

Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?

Problem-solving 

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage 

Does it offer a competitive advantage in the market and within its category?

Recognition of sustainable manufacturing, production or development in the pharmaceutical industry. Including but not limited to, innovative approaches to reducing environmental impact, waste and carbon emissions, energy or utility saving solutions, sustainable and collaborative product development, plastic reduction, improved recyclability or lifecycle management, implementation of circular economy initiatives, innovative use of materials, safeguarding of workers, and programmes or initiatives which seek to improve diversity and inclusion.

Criteria

Innovation 

Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose 

Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Sustainability

Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?

Problem-solving 

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage 

Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services designed to aid and ensure compliance with standards, mandates, and guidance documents established by regulatory authorities.Including, but not limited to, consulting services, development of consortia and industry groups, reference standards, educational programs, case studies, technologies, platforms and equipment.

Criteria

Innovation 

Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose 

Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Sustainability

Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?

Problem-solving 

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage 

Does it offer a competitive advantage in the market and within its category?

C-Suite Executives of SME, Large Pharma/Biopharma or service providers are eligible for nomination. Attributes to be considered include, but are not limited to, financial performance, product performance, global reach, leadership skills, management capability, charitable initiatives, sustainability, regulatory compliance, profitability, vision, marketing, acquisitions, corporate strategy, and financing.

Criteria

Dynamism

Is the nominee an exemplary leader with a strong desire to achieve – are they compelling and progressive? How have they demonstrated exceptional leadership?

Achievements

Has the CEO achieved or accomplished sustained growth, improved performance, implemented robust strategies, engaged staff and customers in their current role or throughout the course of their career?

Leadership

Has the CEO demonstrated consistent personal strengths and attributes that makes them an extraordinary leader?

Contribution to the Wider Industry

Is the CEO committed to the development of the broader pharma industry – this could involve donating goods, funding, time, market insights business intelligence, or contributing to educational programmes.

A new category for 2023, the Start-Up Initiative award seeks to recognise Start-Ups and SMEs driving value and innovation across the pharma value chain. We are looking for entries which demonstrate a clear promise of innovation, growth or sustainable development in pharma.

We understand that Start-Ups are often at different stages of development, and accept entries across proof of concept, protype or commercialised stage.

Entries are reserved exclusively for organisations participating in the CPHI Start-Up Market. [If you are a Start-Up who would like to take part, please visit the Start-Up Brochure for more information]

Criteria

Innovation 

Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose 

Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Sustainability

Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?

Problem-solving 

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage 

Does it offer a competitive advantage in the market and within its category?

This award looks to recognise companies, individuals and initiatives which nurture philanthropic, ethical and community-based ventures. We welcome entries which prioritise patient engagement and centricity, promote corporate social responsibility and improve healthcare accessibility or equity.

Criteria

Innovation 

Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?

Purpose 

Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?

Sustainability

Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?

Problem-solving 

Does it solve a problem? Does it address an issue in an effective way?

Competitive Advantage 

Does it offer a competitive advantage in the market and within its category?